| |
NEWLY AVAILABLE, NEWLY APPROVED
TELESCOPING FITNESS WALKING POLES
|
Exerstrider Products Inc. has introduced
its newest walking pole model, the
Activator™ Medisport Edition.
The Activator™ is Exerstrider’s
first adjustable-length pole utilizing
the same type of “snap button/hole
length adjustment” mechanism
commonly used on canes and walkers.
The new model features the same strapless/safety
ergonomic grips featured on their
other fitness walking poles and it
comes equipped with Exerstrider’s
boot-shaped Cushiongrip™ rubber
tips. An optional bell-shaped balance
tip is available for those for whom
balance is a major concern.
The snap button/length adjustment hole
mechanism was incorporated into the
Activator™ model to provide
greater safety and security to those
with limited hand strength and because
the mechanism is very familiar to
physical therapists and others in
the medical fields.
For more information on the new Exerstrider
Activator™ model, contact,
Exerstrider
P.O. Box 3087
Madison, WI 53714
phone (888) 285-7392
www.exerstrider.com |
NEW ROTATOR CUFF PAIN TECHNOLOGY
|
DePuy Orthopaedics, Inc. announced the launch of a new implant system that offers
hope for patients with debilitating shoulder problems. The new technology,
called the Delta Xtend™ Reverse Shoulder System, reverses the anatomy
of the shoulder to use the healthy deltoid muscle to aid in restoring pain-free
shoulder function in patients with severe rotator cuff pain, helping them return
to their daily activities.
The Delta Xtend System applies scientific and clinical knowledge based on DePuy’s
20-year history with reverse-shoulder implants. The new Delta Xtend System builds
on the success of the Delta CTATM Reverse Shoulder System. The Delta CTA System,
the only reverse shoulder design with over 20 years of clinical heritage, is
designed to optimize two key factors: range-of-motion and recovery time.1,2
The surgical procedure with the Delta Xtend System reverses the anatomy
of the shoulder. The implant is designed so that the ball portion is attached
to the scapula and the socket portion to the humerus. A functional deltoid
muscle is needed for use of this device.
To learn more, contact
DePuy Orthopaedics, Inc.
700 Orthopaedic Drive
Warsaw, IN 46581
Phone (800) 366-8143
www.globalshoulder.com
References
- Nyfeller, RW, et al. “Biomechanical Relevance of Glenoid Component Positioning in the Reverse Delta III Prosthesis.” J
Shoulder Elbow Surg 2005; 14(5): 524-528.
- Middernacht, BO, et al. “Anatomy of the Glenoid: Consequences For Implantation of the Reverse Prosthesis.”
|
NEW LABELING FOR CARTICEL®
|
Genzyme Corporation announced that the U. S. Food and Drug Administration has
approved new labeling for Carticel® (autologous
cultured chondrocytes) based on the completion of a post-approval commitment
study. This label incorporates
safety and efficacy data from the Study of the Treatment of Articular Repair
(STAR) as a result of Genzyme’s successful completion of this final
confirmatory, post-marketing study.
The STAR study investigated the safety and effectiveness of Carticel in patients
who had an inadequate response to a previous cartilage repair procedure in
the knee. Investigators enrolled patients in 29 clinical centers in this prospective
4-year study, which achieved all of its endpoints.
Carticel is used to treat patients who have clinically significant articular
cartilage lesions of the femoral condyle (medial, lateral, trochlea) caused
by acute or repetitive trauma that has not responded to a prior cartilage repair
procedure. Carticel should only be used in conjunction with débridement,
placement of a periosteal flap, and rehabilitation. The independent contributions
of the autologous cultured chondrocytes and other components of the ther-apy
to the outcomes are unknown. Carticel employs a unique process to grow a patient’s
own cartilage cells for implantation to correct certain types of damage.
To learn more, contact
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
Phone (617) 252-7500
fax (617) 252-7600
www.carticel.com
|
|
